Brent L. Saunders

October 8, 2026

BLCO Advances Oral Dry AMD Treatment After FDA Meeting. Bausch + Lomb reported progress on a new oral drug for dry age‑related macular degeneration after a constructive meeting with the FDA. The company said the discussion helped clarify the regulatory pathway and the drug’s development plan. It also announced that its third‑quarter 2026 earnings will be released on Oct. 28, giving investors a future update on performance.

October 1, 2026

SkinHealth Systems Expands SkinStylus MicroSystem to Europe. SkinHealth Systems announced that its SkinStylus® SteriLock® MicroSystem will now be available in European markets. The move expands the company’s footprint beyond North America and could broaden its customer base. The product is a sterilization platform used in dermatology. The news comes as the stock trades near its 52‑week low, but the expansion may support future growth.

September 30, 2026

Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.

October 16, 2026

Cisco Supports 400G Optical Standard for AI Data Centers. Cisco announced it will support a new 400G optical standard aimed at AI data centers, underscoring its push into high‑speed networking for AI workloads. The move comes as analysts note that software renewals could outlast traditional networking upgrade cycles, giving Cisco a steady revenue stream. Industry observers also point to Cisco’s quiet role in wiring data centers for AI, positioning it as a key infrastructure player.

October 16, 2026

BridgeBio Reports Positive Phase 3 Data for Encaleret and Acoramidis. BridgeBio presented new data showing Encaleret improved symptoms in a Phase 3 trial for ADH1, with all participants reporting better outcomes than the standard of care. The company also shared real-world results for Acoramidis, indicating lower composite risk compared to tafamidis in ATTR-CM patients. These updates follow a recent 28% drop in the stock, which analysts suggest may be undervalued relative to their average target price.